Regarding gene rearrangements, a very limited efficacy of ICIs in ALK- [47,51,52,53,54], ROS1- [55,56], RET- [57] and NTRK-rearranged [27] NSCLC patients has been highlighted. This evidence concerns the gene RET and non-small cell lung carcinoma.